Get the Stockscreener App
6.30
0.47%
-0.03
After Hours:
6.29
-0.010
-0.16%
Ardelyx Inc stock is traded at $6.30, with a volume of 3.42M.
It is down -0.47% in the last 24 hours and up +9.00% over the past month.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
See More
Previous Close:
$6.33
Open:
$6.37
24h Volume:
3.42M
Relative Volume:
0.81
Market Cap:
$1.55B
Revenue:
$407.32M
Net Income/Loss:
$-61.60M
P/E Ratio:
-24.46
EPS:
-0.2576
Net Cash Flow:
$-43.98M
1W Performance:
+3.28%
1M Performance:
+9.00%
6M Performance:
+22.81%
1Y Performance:
+35.78%
1-Day Range:
$6.21
$6.46
1-Week Range:
$5.95
$6.505
52-Week Range:
$3.21
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
6.30 | 1.55B | 407.32M | -61.60M | -43.98M | -0.2576 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-03-25 | Resumed | Raymond James | Strong Buy |
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| May-02-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-07-25 | Resumed | Ladenburg Thalmann | Buy |
| Mar-04-25 | Initiated | BTIG Research | Buy |
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
Ardelyx gains after insider purchase, LPGA marketing deal - MSN
Risk On: Can Ardelyx Inc stock outperform in a bear market2026 Earnings Impact & Weekly Stock Breakout Alerts - baoquankhu1.vn
Chart Watch: Is The Bancorp Inc a top pick in the sector2026 Dividend Review & Daily Profit Maximizing Tips - baoquankhu1.vn
Activity Recap: Is Ardelyx Inc stock forming a triangle patternShort Setup & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Aug PostEarnings: How does Ardelyx Inc correlate with Nasdaq2026 Geopolitical Influence & Weekly Setup with High ROI Potential - baoquankhu1.vn
A Look At Ardelyx (ARDX) Valuation After The Appointment Of New Chief Medical Officer - Sahm
Dow Update: Is Ardelyx Inc stock forming a cup and handle2026 Action & Weekly Setup with ROI Potential - baoquankhu1.vn
Earnings Recap: Is Ardelyx Inc affected by consumer sentimentEarnings Miss & Smart Investment Allocation Insights - baoquankhu1.vn
Risk On: Will Ardelyx Inc stock benefit from M AQuarterly Trade Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Ardelyx, Inc. (ARDX) stock price, news, quote and history - Yahoo Finance UK
Could Ardelyx’s New CMO Reframe ARDX’s Long-Term Nephrology Pipeline Strategy? - Sahm
Is Ardelyx (ARDX) Offering Long-Term Value After Recent Share Price Swings? - Yahoo Finance
Ardelyx CMO Appointment Tests Growth Plans For Tenapanor Based Therapies - Yahoo Finance
Ardelyx names Rajani Dinavahi as CMO - The Pharma Letter
Ardelyx, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Ardelyx (ARDX) CMO details 301,000 options at $6.11 and 201,000 shares - Stock Titan
Ardelyx President and CEO Sells 41,000 Shares for $243,000 - Yahoo Finance
Ardelyx President and CEO Sells 41,000 Shares for $243,000 - The Motley Fool
ARDX PE Ratio & Valuation, Is ARDX Overvalued - intellectia.ai
Ardelyx names Rajani Dinavahi as chief medical officer By Investing.com - Investing.com South Africa
Assessing Ardelyx (ARDX) Valuation As New Chief Medical Officer Signals A Fresh Growth Phase - Sahm
Support Test: Is Ardelyx Inc stock forming a triangle pattern2026 Big Picture & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Ardelyx names Rajani Dinavahi as chief medical officer - Investing.com
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx - The Manila Times
Ardelyx, Inc. (NASDAQ:ARDX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Trading Action: Can Ardelyx Inc stock double in the next yearMarket Risk Summary & Community Verified Watchlist Alerts - baoquankhu1.vn
Tech Rally: Is Ardelyx Inc affected by consumer sentiment2026 Institutional Moves & Technical Buy Zone Confirmation - baoquankhu1.vn
Ardelyx Investors Drop Appeal Over U-Turn on Medicare Program - Bloomberg Law News
Ardelyx, Inc. Stock Hits Day Low of $5.26 Amid Price Pressure - Markets Mojo
[SCHEDULE 13G/A] ARDELYX, INC. Amended Passive Investment Disclosure - Stock Titan
Ardelyx Stock Gaps Down Amid Weak Start and Market Concerns - Markets Mojo
Piper Sandler Maintains a Hold Rating on Ardelyx (ARDX) - MSN
Ardelyx's post-earnings decline attributed to concerns over Ibsrela outlook - MSN
ARDX SEC FilingsArdelyx 10-K, 10-Q, 8-K Forms - Stock Titan
ARDX stock is down pre-market after Q4 earnings miss, so why did this firm just hike price target by 80%? - MSN
Can Ardelyx Inc stock outperform in a bear market2026 Short Interest & Stepwise Trade Execution Plans - baoquankhu1.vn
ARDX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Insider Selling: Ardelyx (NASDAQ:ARDX) CEO Sells 41,666 Shares of Stock - MarketBeat
Raab, Ardelyx CEO, sells $243k in ARDX stock By Investing.com - Investing.com South Africa
Raab, Ardelyx CEO, sells $243k in ARDX stock - Investing.com
Ardelyx (ARDX) CEO exercises options, sells 41,666 shares under plan - Stock Titan
Ardelyx, Inc. Opens with 8.38% Gain, Contrasting Recent Performance Trends - Markets Mojo
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):